These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31425728)

  • 41. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of hyposensitization for tree pollinosis on associated apple allergy.
    Herrmann D; Henzgen M; Frank E; Rudeschko O; Jäger L
    J Investig Allergol Clin Immunol; 1995; 5(5):259-67. PubMed ID: 8574432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
    Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
    J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fifty percent of pollinosis patients sensitive to birch pollen demonstrate bronchoconstriction during bronchial provocation test with the allergen].
    Swiebocka E; Siergiejko Z; Siergiejko G; Leoniuk A; Hofman J
    Pol Merkur Lekarski; 2008 Jun; 24(144):492-4. PubMed ID: 18702328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Development of new sensitizations to allergic components in birch pollen extract during specific immunotherapy].
    Modrzyński M; Zawisza E
    Przegl Lek; 2003; 60(3):130-2. PubMed ID: 14575011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study.
    Arvidsson MB; Löwhagen O; Rak S
    Allergy; 2004 Jan; 59(1):74-80. PubMed ID: 14674937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.
    Khinchi MS; Poulsen LK; Carat F; André C; Hansen AB; Malling HJ
    Allergy; 2004 Jan; 59(1):45-53. PubMed ID: 14674933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
    Movérare R; Elfman L; Vesterinen E; Metso T; Haahtela T
    Allergy; 2002 May; 57(5):423-30. PubMed ID: 11972482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy.
    van Hoffen E; Peeters KA; van Neerven RJ; van der Tas CW; Zuidmeer L; van Ieperen-van Dijk AG; Bruijnzeel-Koomen CA; Knol EF; van Ree R; Knulst AC
    J Allergy Clin Immunol; 2011 Jan; 127(1):100-1, 101.e1-3. PubMed ID: 20933256
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical and immunological correlates of pre-co-seasonal sublingual immunotherapy with birch monomeric allergoid in patients with allergic rhinoconjunctivitis.
    Burastero SE; Mistrello G; Paolucci C; Breda D; Roncarolo D; Zanotta S; Falagiani P
    Int J Immunopathol Pharmacol; 2009; 22(2):343-52. PubMed ID: 19505388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.
    Mascarell L; Rak S; Worm M; Melac M; Soulie S; Lescaille G; Lemoine F; Jospin F; Paul S; Caplier L; Hasséus B; Björhn C; Zeldin RK; Baron-Bodo V; Moingeon P
    Allergy; 2015 Apr; 70(4):408-19. PubMed ID: 25631199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical characterization and IgE profiling of birch (Betula verrucosa)--allergic individuals suffering from allergic reactions to raw fruits and vegetables.
    Tolkki L; Alanko K; Petman L; Skydtsgaard MB; Milvang PG; Seppälä U; Ranki A
    J Allergy Clin Immunol Pract; 2013; 1(6):623-31.e1. PubMed ID: 24565710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice.
    Utsch L; Logiantara A; Wallner M; Hofer H; van Ree R; van Rijt LS
    Clin Exp Allergy; 2016 Nov; 46(11):1474-1483. PubMed ID: 27376790
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An observational study on outgrowing food allergy during non-birch pollen-specific, subcutaneous immunotherapy.
    Alonso R; Enrique E; Pineda F; Basagaña M; San Miguel-Moncín MM; Bartra J; Palacios R; Cisteró-Bahíma A
    Int Arch Allergy Immunol; 2007; 143(3):185-9. PubMed ID: 17284927
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Birch-apple syndrome treated with birch pollen immunotherapy.
    Mauro M; Russello M; Incorvaia C; Gazzola G; Frati F; Moingeon P; Passalacqua G
    Int Arch Allergy Immunol; 2011; 156(4):416-22. PubMed ID: 21832831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy.
    Arvidsson MB; Löwhagen O; Rak S
    J Allergy Clin Immunol; 2002 May; 109(5):777-83. PubMed ID: 11994699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
    Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
    Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy.
    Håkansson L; Heinrich C; Rak S; Venge P
    J Allergy Clin Immunol; 1997 Apr; 99(4):551-62. PubMed ID: 9111502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.